lenalidomide (Revlimid)/rituximab (Rituxan) (R2)
Jump to navigation
Jump to search
Indications
- first line therapy for advanced follicular lymphoma
More general terms
References
- ↑ Ingram I Ditching Chemo Appears Viable in Frontline Follicular Lymphoma. PFS 'nearly identical' at 3 years with novel immunomodulatory combination. MedPage Today. June 06, 2018 https://www.medpagetoday.com/meetingcoverage/asco/73327
Fowler NH, et al RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. American Society of Clinical Oncology (ASCO) 2018; Abstract 7500.